Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 0.98 |
| ▸ | LCK | P06239 | 3/20 | 0.98 |
| ▸ | TEK | Q02763 | 3/20 | 0.98 |
| ▸ | MTOR | P42345 | 3/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30499048 | 1.00 | BRAF (1.00) | BRAFRAF1KDRLCKTEK | |
| Hydrochloric Acid SCHEMBL19873385 | 0.99 | BRAF (1.00) | BRAFRAF1KDRLCKTEK | |
| Hydrochloric Acid SCHEMBL19873386 | 0.99 | BRAF (1.00) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL15215289 | 0.88 | BRAF (0.78) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL22223986 | 0.82 | BRAF (0.71) | BRAFRAF1KDRLCKTEK | |
| Lut-014 SCHEMBL25430582 | 0.81 | BRAF (0.69) | BRAFRAF1KDRLCKTEK | |
| Lut-014 SCHEMBL30545866 | 0.81 | BRAF (0.69) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3641288 | 0.80 | BRAF (0.67) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL23015907 | 0.78 | BRAF (0.64) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL11889293 | 0.77 | BRAF (0.76) | BRAFRAF1KDRLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024178274-A2 | METHODS OF DEGRADING RAF(RAF) PROTEIN IN CELLS USING MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1/2 (MEK1/2) PROTEIN DEGRADERS | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-08-29 | — | — | WO | disclosed |
| EP-3284481-B1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | NITTO DENKO CORP (JP) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023140846-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-116271056-A | Cell death inducing agent for cell having BRAF gene mutation, proliferation inhibiting agent for the cell, and pharmaceutical composition for treating disease caused by abnormal proliferation of the cell | 日东电工株式会社 | 2023-06-23 | — | — | CN | disclosed |
| EP-3284481-A1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | Nitto Denko Corporation (JP) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016167340-A1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | 日東電工株式会社 | 2016-10-20 | — | — | WO | disclosed |